This study by Blumenfeld et al. (AJOG, 2014) examined the relationship between placental abruption, maternal characteristics, and routine first- and second-trimester aneuploidy screening analytes.
Population-Based Cohort Study
1,017 women with placental abruption, and 136,898 women without who had first and second trimester prenatal screening results were surveyed. Aneuploidy screening analytes and maternal characteristics were analyzed using logistic binomial regression. Women of Asian descent, those older than 34 years of age, women with chronic and pregnancy-associated hypertension, preexisting diabetes, preeclampsia, previous preterm birth, and an interpregnancy interval of less than 6 months all had more frequent rates of placental abruption. When taking in to account the presence or absence of hypertensive disease, the three factors that remained significantly associated with placental abruption: (1) maternal age older than 34 years, and the two analytes (2) PAPP-A in ≤ 5th percentile and (3) AFP ≥ 95th percentile.
Please log in to ObGFirst to access the 2T US Atlas
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
